Two new genetic loci of Bacillus subtilis are identified by mutations that confer resistance to distamycin A and to other antibacterial agents. The chromosomal region where they map probably contains a cluster of genes whose products are related to membrane structure and function. Some of the biological effects of distamycin A are still in evidence in the resistant mutants indicating that the drug possibly acts at multiple sites. Most biological effects of the drug (including the phenotypic correction of a morphopoietic mutation) are likely to be due to the interaction of distamycin A with membrane (or surface) structures.
Two new genetic loci of Bacillus subtilis are identified by mutations that confer resistance to distamycin A and to other antibacterial agents. The chromosomal region where they map probably contains a cluster of genes whose products are related to membrane structure and function. Some of the biological effects of distamycin A are still in evidence in the resistant mutants indicating that the drug possibly acts at multiple sites. Most biological effects of the drug (including the phenotypic correction of a morphopoietic mutation) are likely to be due to the interaction of distamycin A with membrane (or surface) structures.
Distamycin A (3) is a basic oligopeptide antibiotic with antiviral (6) and antiphagic (8) activities at low concentration (10-5 to 10-6 M), and antibacterial activity at doses 10 times higher. The compound binds to deoxyribonucleic acid (DNA) (14) forming two types of complexes (15) , but none of the reported in vivo activities could be demonstrated to be due to this affinity. Even the inhibition of DNA uptake, genetic transformation, and phage DNA transfection in Bacillus subtilis have been shown to be due to an interaction between distamycin and competent cells rather than with donor DNA (15) . This interpretation fits with other experimental work (8, 19) that indicated the cell surface as the probable site of action of the antibiotic.
In the present work we describe the isolation and characterization of B. subtilis mutants resistant to high doses of distamycin A, and the effect of such a mutation upon distamycin binding, DNA transformation inhibition, and phage lysis inhibition.
We also present data on phenotypic repair by distamycin A of a conditional mutant of B. subtilis defective in spore germination. The following media were employed: NB (nutrient broth, Difco), PY (Penassay broth, Difco), TY (5), minimal medium of Davis and Mingioli (7), and transformation medium MT (17) . When necessary, the media were solidified with 2% Difco agar.
Susceptibility to various chemicals was tested on nutrient agar plates containing increasing concentrations of the drug, added to the melted medium cooled to 45 C. The susceptibility was determined as the minimum inhibitory concentration after 20 h of incubation at 37 C.
Experimental techniques. Spores were prepared as described (9); competent cells were prepared and transformation experiments were performed as previously reported (15 ts-Gsp, thermosensitivity in spore germination.
(green filter). The data are given as transmittance (T percent) or as Klett units. Transduction mapping. Linkage relationships between dst and acf mutations with biochemical markers of known location were determined by PBS-1 transduction following the procedure described by Hoch et al. (10) . After selection on appropriate selective media, transductants were isolated on the same media before testing for unselected markers. Susceptibility to distamycin and acriflavine was tested on nutrient agar plates containing 100 and 6 ,gg/ml, respectively.
Mapping data are expressed as percentages of recombination according to the convention: percentage of recombination = (1-marker co-transfer) x 100.
RESULTS
Selection and characterization of distamycin-resistant mutants. Several distamycin A-resistant (dst) mutants of B. subtilis were obtained from mutagenized PB 168 cultures plated on nutrient agar plates containing 200 jg of distamycin A per ml. One of the mutants (PB 1686) bearing the mutation dst-3 was used for the subsequent work. The marker dst-3 was transferred by transformation into PB 202. Figure 1 (a and b) shows the growth curves of PB 202 and its dst derivate (PB 1689) in the presence of a range of doses of distamycin A. The growth of the parental strain is inhibited by 50 Mg of the antibiotic per ml, whereas the mutant is affected only at doses higher than 100 Mg/ml.
Strain PB 1689 was also tested for its susceptibility to other antibacterial agents, in a search for possible cross-resistances. The data are reported in Table 2 and show that the distamycin-resistant strain is resistant also to acriflavine.
Because of the cross-resistance to acriflavine of the dst 3 strain, we selected acriflavine-resistant mutants and checked their cross-resistance to distamycin and other antibacterial compounds. The two mutants, PB 1717 (acfB6) and PB 1718 (acfBlO), showed cross-resistance to distamycin and to ethidium bromide (Table 2) .
A mutation that confers resistance to acriflavine, here referred to as acfA for reasons that will be apparent below, has been described by Ionesco et al. (12) . This mutation is located between pheA and Iys on the B. subtilis map. Bishop and Brown (4) have described a locus ebr, linked to hisA, that confers resistance to ethidium bromide and cross-resistance to acriflavine. It was then of interest to determine if our dst and acf markers would map in ebr, in acfA, or somewhere else. Chromosomal location of the dst and acfB mutations. Genetic mapping studies, performed with PBS-1 phage-mediated transduction, were carried out to determine the location of the dst and acfB resistance markers.
The results of the crosses reported in Table 3 and 4 allow us to place the dst-3 and acfB6 markers in the same chromosomal region of acfA, but at different positions. The mutation dst-3 is closer to pheA and unlinked to lys, whereas acfB6 is closer to lys and unlinked to pheA. Figure 2 represents the map of the metB-argA region of the B. subtilis chromosome with all the map distances calculated from our crosses, plus the location of the acfA locus described by Ionesco et al. (12 a The resistance to the compounds tested is expressed as minimum inhibitory concentration (gg/ml). The dst mutant seems to bind more distamycin then the wild-type strain: in this experiment they bound 2.6 x 101 and 8.5 x 106 molecules per cell, respectively. The binding increases linearly with cell concentration, and the highest cell concentrations bind approximately 5 and 2% of the radioactive compound initially present in the assay. At each washing a decreasing fraction of the drug is released, indicating that the binding is a rather tight one and not a spurious contamination.
A binding coefficient (nanomoles of distamycin/106 cells) can be calculated from each linear slope in Fig. 3 . Such values can be normalized by the binding coefficient calculated from the first slope (data after the first washing): plotting such a relative binding coefficient versus the number of washings, we obtain the curves depicted in Fig. 4 that represent a measure of the rate of distamycin release from bacterial cells. The mutant strain PB 1689 releases the bound drug at a rate 1.7 times higher than the parental strain PB 202.
The normalized plot in Fig. 4 is independent of the absolute amount of antibiotic bound, and the difference between the two slopes must correspond to a different affinity of the bacterial cells for the antibiotic.
For this kind of measurements we used competent cell cultures since they are a homogeneous population of a short, nonseptated bacilli of uniform length, allowing for a precise evaluation of the cell titer. We attempted to perform analogous measurements with competent cell cultures of mutant acfB6, but such cells lyse at the first washing and are also abnormal in other respects, as we will describe in the following section.
DNA transformation inhibition. The effect of distamycin A on DNA transformation is probably due to an interaction of the drug with the cell envelope (15) . Therefore it was of interest to test the effect of the drug on the distamycin-resistant strain.
We have tested the effect of a range of doses of distamycin A on transformation efficiency: both parental and dst-3 strains show the same response to distamycin, indicating that the mutation does not affect the receptor(s) for DNA.
We were unable to obtain competence with the acfB6 mutant. The competent cells of the mutant are very prone to lysis, even in media of high ionic strength, such as MT, in spite of their 100% viability when seeded on agar plates. SPP1 bacteriophage lysis inhibition by distamycin A. The infection of germinating B. subtilis spores in TY medium by SPP1 bacteriophage leads to an abrupt lysis 180 min after the initiation of infection, even at low multiplicity of infection. Before lysis the presence of the phage does not cause any alteration of the outgrowth as judged by the growth curve (Fig. 5) . In presence of sublethal doses of distamycin A (2 and 3 jg/ml), lysis is completely suppressed (Fig. 5) . A fourfold dilution of the culture with drug-free medium (that reduces the concentration of distamycin A below the minimal protection dose) results in continuation of bacterial growth to plateau values without any sign of lysis. Nevertheless, infection had been successful since the viability of the culture, judged from the colony-forming ability, was reduced to 1% and all cells in the culture are infective centers. If the phage-infected, distamycin Aprotected culture is washed in MT medium it lyses, freeing plaque-forming units in numbers comparable to those obtained in the nonprotected control.
Thus, distamycin A protects B. subtilis cells from phage lysis, possibly by osmotic stabilization of the cells envelopes, but it is ineffective on both phage infection and multiplication.
Identical results were obtained with the distamycin resistant-mutant indicating that antibacterial and lysis inhibition effects of the drug are independent.
These results differ from the ones obtained by Di Marco et al. (8) on the system phage TiEscherichia coli K-12, where both phage adsorption and cell lysis were prevented by distamycin A. Phenotypic repair of a morphopoietic germination mutant. Some membrane-active agents phenotypically repair morphopoietic mutants in a number of systems (see below).
Distamycin seemed to us a good candidate as a membrane-active agent because of its chemical structure and its biological properties. We therefore tested its effect on a series of temperature-sensitive mutants in the process of spore germination (Gsp mutants) that, when germinated at a nonpermissive temperature, give rise to morphologically aberrant forms (9) . We studied the morphology of the spore outgrowth at 46 C in presence of distamycin A in the parental strain PB 1424 and in a number of Gsp mutants. PB 1424 outgrows normally in the presence of 3 gg of distamycin A per ml, and after 2 h only bacillary forms are visible (see Fig. 6A ). Strain PB 2388 is a Gsp mutant that at nonpermissive temperature initiates an abortive septation. The cells formed at 46 C are spherical and are much bigger than the ones formed at 35 C (Fig. 6B) . In the presence of 3 sg of distamycin A per ml at 46 C the spores of this mutant germinate regularly into septated bacillary forms identical to the ones shown in Fig.  6A . Conversely, another mutant tested, PB 2398, defective at an earlier stage of the germination process, stops its outgrowth at 46 C at the "swollen spore" stage both in the absence and presence of a range of doses of distamycin A (Fig. 6C) . DISCUSSION The basic oligopeptide distamycin A interacts (14, 15, 21) with DNA in vitro, but most of the biological effects it displays seem to be unrelated to this property and due to other interactions between the antibiotic and surface structures (15, 19) .
We have isolated a B. subtilis mutant resistant to high doses of distamycin A that is also resistant to acriflavine; and independently isolated acriflavine-resistant mutants show the same cross-resistance to distamycin plus a resistance to ethidium bromide. Two loci, ebr and acfA, involved in acriflavine and ethidium bromide resistances have been mapped by other authors (4, 12) . The mutations described in this paper, acfB and dst, seem to be unrelated to the ones already reported, and map between lys and . This region of the B. subtilis chromosome also contains other resistance markers possibly due to altered drug permeability such as asaA (1) and strC (18) . The hypothesis is that it might contain a cluster of genes whose products are membrane components or related to membrane biosynthesis.
We have studied distamycin binding to competent cells of parental and dst strains. The mutant cells bind as much distamycin as the parental one (or more), but they release the drug at a much higher rate, indicating a different affinity or a lack of permeability. Other biological effects of the drug, such as inhibition of DNA transformation and of phage-induced lysis, are unaffected by the dst mutation, suggesting that the antibacterial effect might operate through a different route as compared to the other biological effects. acfB mutants have a distinct phenotype, are very prone to lysis, and never develop a competence state.
We therefore propose that the biological effects of distamycin A upon B. subtilis cells can be subdivided into at least two groups: those abolished by a mutation (dst) that possibly alters the permeability to the drug, and those due to an interaction of the drug with surface structures.
In view of this, we searched for other biological effects of distamycin A as a possible membrane-active agent in analogy to the findings of Ingram and Fisher (11) who found that filamentous bacterial mutants, defective in cell septation, can be induced to septate by compounds that act on the cell membrane (Na-oleate, lysolecitin, long-chain alcohols), and those of King and Grula (13) who found that, in Micrococcus lysodeicticus, pantoyl lactone can prevent the septation inhibition produced by D-Cycloserine. These authors postulated a physical effect of these compounds on the cytoplasmic membrane, suggesting that a membrane, altered in its chemico-physical properties by the presence of such compounds, might repair cellwall lesions or mimick to some extent cell-wall functions.
We have found that distamycin A is effective in phenotypically correcting a morphopoietic mutant defective in spore outgrowth, unable to complete the first septation.
